Page last updated: 2024-12-08

(5-Phenyl-1,2,4-triazol-3-yl)urea

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

(5-Phenyl-1,2,4-triazol-3-yl)urea is a chemical compound with the formula C8H8N4O. It is a white solid that is soluble in water and ethanol.

**Structure:**

* It consists of a 1,2,4-triazole ring with a phenyl substituent at the 5-position and a urea moiety attached at the 3-position.

**Importance in Research:**

(5-Phenyl-1,2,4-triazol-3-yl)urea has gained interest in research due to its diverse biological activities, including:

* **Antimicrobial activity:** It exhibits antibacterial, antifungal, and antiviral properties, making it a potential candidate for the development of new antimicrobial agents.
* **Anticancer activity:** Studies have shown its potential to inhibit the growth of various cancer cell lines, including leukemia, breast cancer, and colon cancer.
* **Anti-inflammatory activity:** It has demonstrated anti-inflammatory effects, potentially useful for treating inflammatory conditions like arthritis.
* **Neuroprotective activity:** Research suggests its potential to protect against neuronal damage and neurodegenerative diseases.
* **Other potential applications:** It has also been investigated for its potential in treating diabetes, obesity, and cardiovascular diseases.

**Mechanisms of Action:**

The biological activities of (5-Phenyl-1,2,4-triazol-3-yl)urea are attributed to its ability to interact with various biological targets, including:

* **Enzymes:** It can inhibit the activity of enzymes involved in microbial growth, cancer cell proliferation, and inflammation.
* **Receptors:** It can bind to and modulate the activity of receptors involved in signal transduction pathways.
* **DNA:** It can interact with DNA, potentially affecting gene expression and cell cycle regulation.

**Research Focus:**

Current research on (5-Phenyl-1,2,4-triazol-3-yl)urea focuses on:

* Identifying its precise mechanisms of action.
* Optimizing its pharmacological properties, such as bioavailability and selectivity.
* Developing novel drug formulations for various therapeutic applications.
* Conducting preclinical and clinical trials to evaluate its safety and efficacy in humans.

**Conclusion:**

(5-Phenyl-1,2,4-triazol-3-yl)urea is a promising compound with a wide range of biological activities that has the potential to contribute to the development of new therapeutic agents for various diseases. Its diverse pharmacological profile and ongoing research make it an important molecule for future drug discovery and development.

Cross-References

ID SourceID
PubMed CID222304
CHEMBL ID1602886
CHEBI ID79884
SCHEMBL ID8964965

Synonyms (36)

Synonym
nsc8179 ,
6642-32-6
nsc-8179
mls000737892 ,
NCI60_041793
(5-phenyl-1,2,4-triazol-3-yl)urea
3-phenyl-5-ureido-1,2,4-triazole
nsc67820
nsc-69198
nsc-67820
nsc69198
n-(3-phenyl-1h-1,2,4-triazol-5-yl)urea
NCGC00013091
nsc-163498
nsc163498
NCI8179
smr000528078
NCISTRUC2_000270
NCISTRUC1_000236
NCGC00096214-01
1-(5-phenyl-1h-1,2,4-triazol-3-yl)urea
(5-phenyl-1h-1,2,4-triazol-3-yl)urea
AKOS024332305
HMS2885G24
CCG-38112
NCGC00013091-02
SCHEMBL8964965
CHEBI:79884 ,
CHEMBL1602886
66H22XI3IX ,
urea, n-(3-phenyl-1h-1,2,4-triazol-5-yl)-
unii-66h22xi3ix
Q27149032
DTXSID80985083
n-(5-phenyl-1,2-dihydro-3h-1,2,4-triazol-3-ylidene)carbamimidic acid
1-(3-phenyl-1h-1,2,4-triazol-5-yl)urea
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzenesAny benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATAD5 protein, partialHomo sapiens (human)Potency16.35350.004110.890331.5287AID504467
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency23.10930.00419.984825.9290AID504444
eyes absent homolog 2 isoform aHomo sapiens (human)Potency89.12511.199814.641950.1187AID488837
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1224817Assays to identify small molecules inhibitory for eIF4E expression2015Chemistry & biology, Jul-23, Volume: 22, Issue:7
Internal Ribosome Entry Site-Based Bicistronic In Situ Reporter Assays for Discovery of Transcription-Targeted Lead Compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.35

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.35 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.35)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]